Changing the course of cancer treatment
We harness the power of the body's immune system to keep tumor cells in check without harming health or quality of life.
Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in an established...
Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)
Immunicum announced that it has been granted an Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for ilixadencel in the treatment of Gastrointestinal Stromal Tumors (GIST).
Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment
Immunicum announced today updated interim results from the ongoing ADVANCE II clinical trial evaluating the company’s lead development program DCP-001, a novel therapeutic option for acute myeloid leukemia (AML) maintenance therapy in patients with measurable residual disease (MRD).
Publication of 2021 Annual Report
Annual General Meeting
Publication of Q1 Report
Publication of Q2 Report
Publication of Q3 Report
Publication of Year-end Report 2022
Publication of Q2 2022 Results
Mendus will publish the results of the second quarter and first six month of 2022 on August 26th, 2022 at 8am CET.
Keep up to date
Join our mailing list to receive our latest news.